Foamix Pharmaceuticals Ltd (NASDAQ:FOMX) Receives $15.40 Consensus Target Price from Analysts

Shares of Foamix Pharmaceuticals Ltd (NASDAQ:FOMX) have earned a consensus rating of “Buy” from the seven analysts that are covering the firm, Marketbeat.com reports. Two research analysts have rated the stock with a hold rating and five have issued a buy rating on the company. The average 1 year price target among brokers that have updated their coverage on the stock in the last year is $15.40.

FOMX has been the topic of several recent analyst reports. HC Wainwright reiterated a “buy” rating and issued a $11.00 price target (up from $10.00) on shares of Foamix Pharmaceuticals in a research note on Monday, October 21st. Cowen set a $30.00 price target on shares of Foamix Pharmaceuticals and gave the company a “buy” rating in a research note on Monday, September 23rd. Finally, Zacks Investment Research upgraded shares of Foamix Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Tuesday, October 22nd.

Shares of Foamix Pharmaceuticals stock opened at $2.90 on Tuesday. The firm has a market capitalization of $169.67 million, a P/E ratio of -1.71 and a beta of 1.53. Foamix Pharmaceuticals has a 52 week low of $1.97 and a 52 week high of $4.48. The company has a quick ratio of 5.72, a current ratio of 5.72 and a debt-to-equity ratio of 0.24. The firm’s 50 day moving average is $3.31 and its two-hundred day moving average is $2.90.

Foamix Pharmaceuticals (NASDAQ:FOMX) last announced its quarterly earnings results on Monday, November 11th. The specialty pharmaceutical company reported ($0.41) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.34) by ($0.07). Foamix Pharmaceuticals had a negative net margin of 2,115.11% and a negative return on equity of 100.58%. As a group, research analysts expect that Foamix Pharmaceuticals will post -1.66 earnings per share for the current fiscal year.

A number of institutional investors have recently made changes to their positions in FOMX. Sofinnova Investments Inc. boosted its holdings in shares of Foamix Pharmaceuticals by 34.1% in the second quarter. Sofinnova Investments Inc. now owns 1,115,810 shares of the specialty pharmaceutical company’s stock valued at $2,655,000 after acquiring an additional 283,517 shares during the period. DLD Asset Management LP boosted its holdings in shares of Foamix Pharmaceuticals by 75.0% in the second quarter. DLD Asset Management LP now owns 525,000 shares of the specialty pharmaceutical company’s stock valued at $1,250,000 after acquiring an additional 225,000 shares during the period. Renaissance Technologies LLC boosted its holdings in shares of Foamix Pharmaceuticals by 1,759.8% in the second quarter. Renaissance Technologies LLC now owns 323,600 shares of the specialty pharmaceutical company’s stock valued at $770,000 after acquiring an additional 306,200 shares during the period. ARK Investment Management LLC boosted its holdings in shares of Foamix Pharmaceuticals by 25.0% in the second quarter. ARK Investment Management LLC now owns 146,745 shares of the specialty pharmaceutical company’s stock valued at $349,000 after acquiring an additional 29,378 shares during the period. Finally, JPMorgan Chase & Co. boosted its holdings in shares of Foamix Pharmaceuticals by 24.3% in the second quarter. JPMorgan Chase & Co. now owns 112,536 shares of the specialty pharmaceutical company’s stock valued at $270,000 after acquiring an additional 22,027 shares during the period. Institutional investors own 47.29% of the company’s stock.

About Foamix Pharmaceuticals

Foamix Pharmaceuticals Ltd., a late clinical-stage specialty pharmaceutical company, develops and commercializes foam-based formulations for dermatological therapy in the United States, France, Denmark, and Germany. Its lead product candidates include FMX101, a novel topical foam formulation of the antibiotic minocycline that has completed third pivotal Phase III clinical trial for the treatment of moderate-to-severe acne; and FMX103, which is in Phase III clinical trial for the treatment of moderate-to-severe papulopustular rosacea.

Featured Story: What is the S&P/ASX 200 Index?

Analyst Recommendations for Foamix Pharmaceuticals (NASDAQ:FOMX)

Receive News & Ratings for Foamix Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Foamix Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit